Download Files:
Products Details
Product Description
– LASSBio-1632 is a new anti-asthmatic lead candidate associated with selective inhibition of PDE4A and PDE4D isoenzymes and blockade of airway hyper-reactivity (AHR) and TNF-α production in the lung tissue. LASSBio-1632 (7j) displays high experimental BBB permeability across BBB through passive diffusion[1].
Web ID
– HY-131340
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C18H20N2O6S
References
– [1]Isabelle Karine da Costa Nunes, et al. Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies. Eur J Med Chem. 2020 Jul 18;204:112492.
Molecular Weight
– 392.43
SMILES
– CC1=CC2=C(C=C1S(N(/N=C/C3=CC=C(C(OC)=C3)OC)C)(=O)=O)OCO2
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– Phosphodiesterase (PDE)
Isoform
– PDE4
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
